Recent advancements in artificial intelligence (AI) hold great promise in oncology, including prostate cancer care. Despite its promises, there is a lack of comprehensive synthesis and knowledge ...

Daniel W. Lin, MD, reviews new guidance on using MRI, biomarkers, and more, to improve the detection of prostate cancer.

Prostate cancer diagnosis heavily relies on histopathological evaluation, which is subject to variability. While immunohistochemical staining (IHC) assists in distinguishing benign from malignant ...

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

Health insurers and health care provider organizations are increasingly using artificial intelligence (AI) tools in prior authorization and claims processes. AI offers many potential benefits, but its ...